Literature DB >> 21284491

Pregnancy outcome in patients with fibromyalgia syndrome.

Tammy Zioni1, Dan Buskila, Barak Aricha-Tamir, Arnon Wiznitzer, Eyal Sheiner.   

Abstract

OBJECTIVE: To investigate pregnancy outcome of patients with fibromyalgia syndrome (FMS).
METHODS: A retrospective cohort study comparing pregnancies of women with and without FMS was conducted. Multivariable logistic regression models was performed to control for confounders
RESULTS: Deliveries of 112 women with FMS were compared with a control group of 487 deliveries of women without FMS. Parturients with FMS had higher rates of intrauterine growth restriction (IUGR; 7.1% vs. 1.0%, p = 0.001), recurrent abortions (9.8% vs. 1.8%, p < 0.001), gestational diabetes mellitus (14.3% vs. 7%, p = 0.012), and polyhydramnios (12.5% vs. 1.6%, p < 0.001). These patients had lower rates of preterm deliveries (PTD; 6.3% vs. 16.7%, p = 0.018). No significant differences were noted between the groups regarding the rates of cesarean deliveries (CD) (15.2% vs. 21.2%, p = 0.149) and perinatal outcomes such as low Apgar scores (<7) at 1 and 5 min (4.5% vs. 6.7%, p = 0.292 and 1.2% vs. 0.6%, p = 0.372; respectively). Using two multiple logistic regression models, the positive association between FMS and IUGR (adjusted OR = 4.1, 95% CI 1.2-13.2; p = 0.02) and the negative association with PTD (OR = 0.3, 95% CI 0.2-0.6; p = 0.001) remained significant.
CONCLUSION: FMS is an independent risk factor for intrauterine growth restriction. Nevertheless, it is associated with lower rates of preterm deliveries.

Entities:  

Mesh:

Year:  2011        PMID: 21284491     DOI: 10.3109/14767058.2010.551152

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  1 in total

1.  High prevalence of fibromyalgia symptoms among healthy full-term pregnant women.

Authors:  Sharon Saa'd; Ariel Many; Giris Jacob; Jacob N Ablin
Journal:  Rheumatol Int       Date:  2012-12-22       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.